CLIC-1901 for CD19-positive blood and lymphoma cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial studies a gene-modified cell treatment called CLIC-1901 for people whose CD19-positive cancer has come back or did not respond to prior treatment. It may help shrink the cancer by targeting a protein called CD19 on cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a CD19-positive blood cancer or B-cell lymphoma that has relapsed or is hard to treat (refractory).
- Your cancer must show CD19 in a recent test (tissue, bone marrow, or blood) within 3 months of screening.
- You are between 18 and 75 years old and can sign informed consent.
- Your kidneys, liver, and other organs must be healthy enough for treatment (adequate organ function).
- You must not have certain major exclusions, like isolated outside-the-bone-medical-center disease (isolated extra-medullary disease).
- You must not have recent immune system complications like active graft-versus-host disease needing medicine, or recent certain transplant-related treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This Phase 2 trial tests whether an injected cell therapy called CNCT19 can treat non-Hodgkin lymphoma that has come back or did not respond to prior treatment. It may help by targeting specific lymphoma cells, but you must meet several safety and medical eligibility checks.
This early-phase study tests a treatment called CD19 CAR-T, made from your immune cells, for people whose CD19+ blood cancer has come back or did not respond. It may help your body better recognize and attack cancer cells, but eligibility is tight and the study is still early.
This Phase 1/2 trial studies an “off-the-shelf” (allogeneic) immune-cell therapy that targets CD19, a marker on many B-cell lymphomas. It’s for adults whose lymphoma has come back or didn’t respond to prior treatment, aiming to shrink tumors and improve outcomes.
Hear when a new Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.